Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Botanix Pharmaceuticals Limited (BOT.AX)
AUD0.03
+0.00 (+4.00%)
AU ASX Healthcare Biotechnology
Address
D2, 661 Newcastle Street 6007
Leederville, WA, AU
Leederville, WA, AU
CEO
Howie McKibbon
Website
botanixpharma.com
IPO
1988-01-31
ISIN AU000000BOT2
Also trades on
Australian Securities Exchange · BOT.AX (AUD)
Other OTC · BXPHF (USD)
Description
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.03
+0.00 (+4.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
22M
Beta
0.83
Float Shares
1.45B
Free Float %
72.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.35% | -7.69% | -14.29% | -57.14% | -80.00% | -82.22% | -93.51% | -72.09% | -65.22% | -20.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.03
DCF (Unlevered)
0.01
-78.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-5.76
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+862.0% ★ Q4'25: +4,267.4% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-408.7% Q4'25: -344.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,026.7% Q4'25: -197.8% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-1,432.2% Q4'25: -203.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-169.7% Q4'25: -253.5% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+22.9% Q4'25: +36.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.40× Q4'25: -0.24× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 1996 actual |
Jun 1997 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 3 Rev. Ana. 2 EPS Ana. |
Jun 2027 3 Rev. Ana. 2 EPS Ana. |
Jun 2028 3 Rev. Ana. 2 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
Jun 2030 2 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
41.33M
est: 41.92M (-1.4%)
|
—
est: 36.54M (-100.0%)
|
4.69M
est: 3.30M (+42.0%)
|
7.57M
est: 7.60M (-0.3%)
|
6.89M
est: 7.00M (-1.6%)
|
2.76M
est: 48.20M (-94.3%)
|
915.0K
est: 117.83M (-99.2%)
|
601.8K
est: 400.0K (+50.5%)
|
5.79M
est: 4.60M (+25.9%)
|
34.81M
32.67M – 37.63M
+656.8% YoY
|
73.83M
59.52M – 83.48M
+112.1% YoY
|
139.08M
135.49M – 142.67M
+88.4% YoY
|
38.40M
32.61M – 42.79M
-72.4% YoY
|
70.21M
59.63M – 78.25M
+82.9% YoY
|
| EBITDA |
5.17M
est: -41.92M (+112.3%)
|
-14.40M
est: -35.82M (+59.8%)
|
-17.16M
est: -3.19M (-438.3%)
|
-24.14M
est: -7.60M (-217.6%)
|
-10.06M
est: -6.76M (-48.8%)
|
-15.75M
est: -299.1K (-5,164.2%)
|
-12.63M
est: -998.6K (-1,164.9%)
|
-15.25M
est: -392.8K (-3,783.7%)
|
-80.65M
est: -4.60M (-1,653.3%)
|
-34.81M
-37.63M – -32.67M
-656.8% YoY
|
-73.83M
-83.48M – -59.52M
-112.1% YoY
|
-139.08M
-142.67M – -135.49M
-88.4% YoY
|
-38.40M
-42.79M – -32.61M
+72.4% YoY
|
-70.21M
-78.25M – -59.63M
-82.9% YoY
|
| EBIT |
84.0K
est: -41.92M (+100.2%)
|
—
est: -35.82M (+100.0%)
|
-17.16M
est: -3.19M (-438.3%)
|
-24.24M
est: -7.60M (-219.0%)
|
-10.16M
est: -6.76M (-50.2%)
|
-15.89M
est: -299.1K (-5,212.0%)
|
-12.74M
est: -998.6K (-1,176.0%)
|
-15.33M
est: -392.8K (-3,802.2%)
|
-82.91M
est: -4.60M (-1,702.5%)
|
-34.81M
-37.63M – -32.67M
-656.8% YoY
|
-73.83M
-83.48M – -59.52M
-112.1% YoY
|
-139.08M
-142.67M – -135.49M
-88.4% YoY
|
-38.40M
-42.79M – -32.61M
+72.4% YoY
|
-70.21M
-78.25M – -59.63M
-82.9% YoY
|
| Net Income |
—
est: 6.26T (-100.0%)
|
132.0K
est: -4.46T (+100.0%)
|
-17.04M
est: -88.16M (+80.7%)
|
-16.73M
est: -33.21M (+49.6%)
|
-3.33M
est: -22.92M (+85.5%)
|
-13.17M
est: -299.1K (-4,303.6%)
|
-9.15M
est: -998.6K (-816.7%)
|
-13.87M
est: -13.51M (-2.6%)
|
-86.40M
est: -63.16M (-36.8%)
|
-38.13M
-43.10M – -33.16M
+39.6% YoY
|
-19.06M
-23.46M – -14.66M
+50.0% YoY
|
3.40M
-6.46M – 32.29M
+117.8% YoY
|
59.04M
47.48M – 67.83M
+1,636.4% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
—
est: 289.22M (-100.0%)
|
—
est: 247.14M (-100.0%)
|
4.83M
est: 21.99M (-78.0%)
|
9.68M
est: 52.44M (-81.5%)
|
3.19M
est: 46.65M (-93.2%)
|
4.62M
est: 321.22M (-98.6%)
|
5.93M
est: 1.94M (+205.6%)
|
6.98M
est: 2.76M (+152.9%)
|
82.67M
est: 31.74M (+160.5%)
|
240.19M
225.43M – 259.64M
+656.8% YoY
|
509.37M
410.62M – 575.97M
+112.1% YoY
|
959.58M
934.80M – 984.37M
+88.4% YoY
|
264.92M
225.00M – 295.25M
-72.4% YoY
|
484.43M
411.44M – 539.90M
+82.9% YoY
|
| EPS |
194.76
est: 3,393.26 (-94.3%)
|
-540.36
est: -2,456.07 (+78.0%)
|
-0.02
est: -0.05 (+55.2%)
|
-0.02
est: -0.02 (+0.6%)
|
0.00
est: -0.01 (+73.8%)
|
-0.01
est: 0.03 (-140.9%)
|
-0.01
est: -0.01 (-31.7%)
|
-0.01
est: -0.01 (-22.7%)
|
-0.05
est: -0.03 (-38.7%)
|
-0.02
-0.02 – -0.02
+38.8% YoY
|
-0.01
-0.01 – -0.01
+50.0% YoY
|
0.01
0.00 – 0.02
+167.7% YoY
|
0.03
0.03 – 0.04
+357.1% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-114.25M
OE per share TTM
-0.06
Owner's Yield
-242.36%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
8.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
2.6K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
1
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ANCORA ADVISORS, LLC | — -25.0K (-100.0%) | — -2.6K (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | AUD— | 5 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.00% | 9.4K | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-75.4K
Shares Outstanding
1.99B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vincent Ippolito | MD & Executive Chairman | 1M | male |
| Howie McKibbon | Chief Executive Officer | 959.2K | — |
| Chris Lesovitz | Chief Financial Officer of United States of America | 641.2K | male |
| Paul Seaback | Chief Operating Officer | 526.6K | male |
| Graeme Morissey | Chief Financial Officer | 125.0K | male |
| Andrew Bickley | Joint Company Secretary | — | male |
| David Morgan | Head of Corporate Affairs | — | male |
| Kevin Wojciechowski | Head of HCP Marketing & Sales Training | — | male |
| Darin Van Arsdale | Director of Sales Operations | — | male |
| Boris Meyerson | Chief Business Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BOT.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
